CARECLOUD INC (CCLD) Stock Fundamental Analysis
NASDAQ:CCLD - US14167R1005 - Common Stock
2.83 USD
+0.11 (+4.04%)
2.76 USD
-0.07 (-2.47%)
Overall CCLD gets a fundamental rating of 5 out of 10. We evaluated CCLD against 35 industry peers in the Health Care Technology industry. While CCLD has a great health rating, its profitability is only average at the moment. CCLD has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
CCLD had negative earnings in the past year.
CCLD had a positive operating cash flow in the past year.
CCLD had negative earnings in each of the past 5 years.
CCLD had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of 0.02%, CCLD belongs to the best of the industry, outperforming 83.33% of the companies in the same industry.
CCLD has a better Return On Equity (0.02%) than 83.33% of its industry peers.
The Return On Invested Capital of CCLD (16.12%) is better than 97.22% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.02% | ||
| ROE | 0.02% | ||
| ROIC | 16.12% |
ROA(3y)-32.11%
ROA(5y)-24.15%
ROE(3y)-57.71%
ROE(5y)-41.4%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CCLD has a Profit Margin of 0.01%. This is amongst the best in the industry. CCLD outperforms 83.33% of its industry peers.
The Operating Margin of CCLD (10.77%) is better than 88.89% of its industry peers.
CCLD's Operating Margin has improved in the last couple of years.
The Gross Margin of CCLD (46.00%) is worse than 63.89% of its industry peers.
In the last couple of years the Gross Margin of CCLD has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.77% | ||
| PM (TTM) | 0.01% | ||
| GM | 46% |
OM growth 3Y59.79%
OM growth 5Y95.05%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.11%
GM growth 5Y4.51%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), CCLD is creating some value.
CCLD has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CCLD has been increased compared to 5 years ago.
The debt/assets ratio for CCLD has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 4.85 indicates that CCLD is not in any danger for bankruptcy at the moment.
The Altman-Z score of CCLD (4.85) is better than 80.56% of its industry peers.
CCLD has a debt to FCF ratio of 0.02. This is a very positive value and a sign of high solvency as it would only need 0.02 years to pay back of all of its debts.
CCLD's Debt to FCF ratio of 0.02 is amongst the best of the industry. CCLD outperforms 86.11% of its industry peers.
CCLD has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of CCLD (0.00) is better than 72.22% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.02 | ||
| Altman-Z | 4.85 |
ROIC/WACC1.58
WACC10.19%
2.3 Liquidity
CCLD has a Current Ratio of 1.91. This is a normal value and indicates that CCLD is financially healthy and should not expect problems in meeting its short term obligations.
CCLD's Current ratio of 1.91 is in line compared to the rest of the industry. CCLD outperforms 47.22% of its industry peers.
CCLD has a Quick Ratio of 1.88. This is a normal value and indicates that CCLD is financially healthy and should not expect problems in meeting its short term obligations.
CCLD's Quick ratio of 1.88 is in line compared to the rest of the industry. CCLD outperforms 47.22% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.91 | ||
| Quick Ratio | 1.88 |
3. Growth
3.1 Past
CCLD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 95.70%, which is quite impressive.
CCLD shows a small growth in Revenue. In the last year, the Revenue has grown by 0.04%.
CCLD shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.47% yearly.
EPS 1Y (TTM)95.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%128.57%
Revenue 1Y (TTM)0.04%
Revenue growth 3Y-7.4%
Revenue growth 5Y11.47%
Sales Q2Q%-2.54%
3.2 Future
CCLD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 63.19% yearly.
Based on estimates for the next years, CCLD will show a small growth in Revenue. The Revenue will grow by 3.92% on average per year.
EPS Next Y152.7%
EPS Next 2Y63.19%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year0.43%
Revenue Next 2Y3.92%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CCLD. In the last year negative earnings were reported.
CCLD is valuated rather expensively with a Price/Forward Earnings ratio of 21.34.
Based on the Price/Forward Earnings ratio, CCLD is valued cheaper than 80.56% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.81, CCLD is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 21.34 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CCLD is valued cheaper than 100.00% of the companies in the same industry.
100.00% of the companies in the same industry are more expensive than CCLD, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.88 | ||
| EV/EBITDA | 4.7 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of CCLD may justify a higher PE ratio.
CCLD's earnings are expected to grow with 63.19% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y63.19%
EPS Next 3YN/A
5. Dividend
5.1 Amount
CCLD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
2.83
+0.11 (+4.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners16.98%
Inst Owner ChangeN/A
Ins Owners14.3%
Ins Owner Change2.36%
Market Cap119.77M
Analysts80
Price Target3.7 (30.74%)
Short Float %3.09%
Short Ratio2.86
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.92
Dividend Growth(5Y)21.2%
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)58.82%
Min EPS beat(2)21.57%
Max EPS beat(2)96.08%
EPS beat(4)4
Avg EPS beat(4)72.28%
Min EPS beat(4)21.57%
Max EPS beat(4)100%
EPS beat(8)5
Avg EPS beat(8)-0.12%
EPS beat(12)8
Avg EPS beat(12)-1.47%
EPS beat(16)12
Avg EPS beat(16)11.57%
Revenue beat(2)1
Avg Revenue beat(2)2.17%
Min Revenue beat(2)-1.27%
Max Revenue beat(2)5.6%
Revenue beat(4)1
Avg Revenue beat(4)0.34%
Min Revenue beat(4)-1.89%
Max Revenue beat(4)5.6%
Revenue beat(8)1
Avg Revenue beat(8)-2.29%
Revenue beat(12)1
Avg Revenue beat(12)-3.19%
Revenue beat(16)3
Avg Revenue beat(16)-2.21%
PT rev (1m)-17.93%
PT rev (3m)-13%
EPS NQ rev (1m)-21.43%
EPS NQ rev (3m)197.79%
EPS NY rev (1m)3.33%
EPS NY rev (3m)3.33%
Revenue NQ rev (1m)-2.08%
Revenue NQ rev (3m)-3.62%
Revenue NY rev (1m)-0.52%
Revenue NY rev (3m)-0.52%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 21.34 | ||
| P/S | 1.07 | ||
| P/FCF | 6.88 | ||
| P/OCF | 4.83 | ||
| P/B | 2.14 | ||
| P/tB | 5.6 | ||
| EV/EBITDA | 4.7 |
EPS(TTM)-0.04
EYN/A
EPS(NY)0.13
Fwd EY4.69%
FCF(TTM)0.41
FCFY14.54%
OCF(TTM)0.59
OCFY20.72%
SpS2.64
BVpS1.33
TBVpS0.51
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.02% | ||
| ROE | 0.02% | ||
| ROCE | 20.4% | ||
| ROIC | 16.12% | ||
| ROICexc | 16.12% | ||
| ROICexgc | 39.14% | ||
| OM | 10.77% | ||
| PM (TTM) | 0.01% | ||
| GM | 46% | ||
| FCFM | 15.58% |
ROA(3y)-32.11%
ROA(5y)-24.15%
ROE(3y)-57.71%
ROE(5y)-41.4%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y52.71%
ROICexcg growth 5Y104.32%
ROICexc growth 3Y91.65%
ROICexc growth 5Y92.03%
OM growth 3Y59.79%
OM growth 5Y95.05%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.11%
GM growth 5Y4.51%
F-Score7
Asset Turnover1.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.02 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 54.79% | ||
| Cap/Sales | 6.62% | ||
| Interest Coverage | 63.03 | ||
| Cash Conversion | 97.14% | ||
| Profit Quality | 124386% | ||
| Current Ratio | 1.91 | ||
| Quick Ratio | 1.88 | ||
| Altman-Z | 4.85 |
F-Score7
WACC10.19%
ROIC/WACC1.58
Cap/Depr(3y)74.91%
Cap/Depr(5y)76.9%
Cap/Sales(3y)8.36%
Cap/Sales(5y)8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)95.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%128.57%
EPS Next Y152.7%
EPS Next 2Y63.19%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)0.04%
Revenue growth 3Y-7.4%
Revenue growth 5Y11.47%
Sales Q2Q%-2.54%
Revenue Next Year0.43%
Revenue Next 2Y3.92%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15735.1%
EBIT growth 3Y47.96%
EBIT growth 5Y117.42%
EBIT Next Year208.61%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y112.11%
FCF growth 3Y68.43%
FCF growth 5Y21.21%
OCF growth 1Y21.45%
OCF growth 3Y15.69%
OCF growth 5Y22.06%